Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease

키워드

참고문헌 (42)

1. Torres J, "Crohn’s disease", Lancet, 389, pp.1741~1755 (2017)
2. Koh SJ, "Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease", Intest Res, 21, pp.43~60 (2023)
3. Park SH, "Update on the epidemiology of inflammatory bowel disease in Asia : where are we now?", Intest Res, 20, pp.159~164 (2022)
4. Usami M, "Clinical features of very early-onset inflammatory bowel disease in Japan : a retrospective single-center study", Intest Res, 20, pp.475~481 (2022)
5. Kang B, "Early biologic treatment in pediatric Crohn’s disease : catching the therapeutic window of opportunity in early disease by treat-to-target", Pediatr Gastroenterol Hepatol Nutr, 21, pp.1~11 (2018)
6. Kang B, "Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn’s disease under combined immunosuppression : escalation versus early treatment", J Crohns Colitis, 10, pp.1279~1286 (2016)
7. Tajra JB, "Correlation and concordance measures between clinical, endoscopic and histological scores activity in Crohn’s disease under treatment", Scand J Gastroenterol, 54, pp.441~445 (2019)
8. Laterza L, "Multiparametric evaluation predicts different mid-term outcomes in Crohn’s disease", Dig Dis, 36, pp.184~193 (2018)
9. Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : Determining Therapeutic Goals for Treat-to-Target", Am J Gastroenterol, 110, pp.1324~1338 (2015)
10. Buisson A, "Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn’s disease", J Gastroenterol, 54, pp.312~320 (2019)
11. Baert F, "Mucosal healing predicts sustained clinical remission in patients with earlystage Crohn’s disease", Gastroenterology, 138, pp.463~468 (2010)
12. Colombel JF, "Effect of tight control management on Crohn’s disease(CALM) : a multicentre, randomised, controlled phase 3 trial", Lancet, 390, pp.2779~2789 (2017)
13. Lee YM, "Association between fecal calprotectin and mucosal healing in pediatric patients with Crohn’s disease who have achieved sustained clinical remission with anti-tumor necrosis factor agents", Gut Liver, 16, pp.62~70 (2022)
14. D’Haens G, "Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease", Inflamm Bowel Dis, 18, pp.2218~2224 (2012)
15. Levine A, "ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents", J Pediatr Gastroenterol Nutr, 58, pp.795~806 (2014)
16. Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
17. Turner D, "STRIDE-II : An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)Initiative of the International Organization for the Study of IBD(IOIBD) : Determining Therapeutic Goals for Treat-to-Target strategies in IBD", Gastroenterology, 160, pp.1570~1583 (2021)
18. Hyams JS, "Development and validation of a pediatric Crohn’s disease activity index", J Pediatr Gastroenterol Nutr, 12, pp.439~447 (1991)
19. Kugathasan S, "Prediction of complicated disease course for children newly diagnosed with Crohn’s disease : a multicentre inception cohort study", Lancet, 389, pp.1710~1718 (2017)
20. Levine A, "Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn’s disease : evaluation of the porto IBD group"growth relapse and outcomes with therapy"(GROWTH CD)study", Inflamm Bowel Dis, 20, pp.278~285 (2014)
21. Ziv-Baran T, "Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease", Aliment Pharmacol Ther, 48, pp.1242~1250 (2018)
22. Levine A, "Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn’s disease : results from the Porto Group GROWTH Study", J Crohns Colitis, 14, pp.71~78 (2020)
23. Ruemmele FM, "Consensus guidelines of ECCO", ESPGHAN on the medical management of pediatric Crohn’s disease, 2014, pp.8, 1179~1207
24. Zubin G, "Predicting endoscopic Crohn’s disease activity before and after induction therapy in children : a comprehensive assessment of PCDAI, CRP, and fecal calprotectin", Inflamm Bowel Dis, 21, pp.1386~1391 (2015)
25. Turner D, "Which PCDAI version best reflects intestinal inflammation in pediatric Crohn disease?", J Pediatr Gastroenterol Nutr, 64, pp.254~260 (2017)
26. Cellier C, "Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease : a prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives", Gut, 35, pp.231~235 (1994)
27. Tibble JA, "Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease", Gastroenterology, 119, pp.15~22 (2000)
28. Kostas A, "Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease", World J Gastroenterol, 23, pp.7387~7396 (2017)
29. Mosli MH, "C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients : a systematic review and meta-analysis", Am J Gastroenterol, 110, pp.802~819 (2015)
30. Schoepfer AM, "Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease(SES-CD)than CRP, blood leukocytes, and the CDAI", Am J Gastroenterol, 105, pp.162~169 (2010)
31. Foster AJ, "Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients", World J Gastroenterol, 25, pp.1266~1277 (2019)
32. Laharie D, "Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders : a prospective study", Aliment Pharmacol Ther, 34, pp.462~469 (2011)
33. Mao R, "Fecal calprotectin in predicting relapse of inflammatory bowel diseases : a meta-analysis of prospective studies", Inflamm Bowel Dis, 18, pp.1894~1899 (2012)
34. Guidi L, "Faecal calprotectin assay after induction with anti-tumour necrosis factor αagents in inflammatory bowel disease : prediction of clinical response and mucosal healing at one year", Dig Liver Dis, 46, pp.974~979 (2014)
35. Molander P, "Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents", Inflamm Bowel Dis, 18, pp.2011~2017 (2012)
36. Bouguen G, "Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease", Clin Gastroenterol Hepatol, 12, pp.978~985 (2014)
37. Dulai PS, "Prognostic value of fecal calprotectin to inform treat-totarget monitoring in ulcerative colitis", Clin Gastroenterol Hepatol, 21, pp.456~466 (2023)
38. Lee SH, "Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis", BMC Gastroenterol, 17, pp.110~ (2017)
39. Costa F, "Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease", Gut, 54, pp.364~368 (2005)
40. Kang B, "Korean children and adolescents with Crohn’s disease are more likely to present with perianal fistulizing disease at diagnosis compared to their European counterparts", Pediatr Gastroenterol Hepatol Nutr, 23, pp.49~62 (2020)
41. Stevens TW, "Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas", United European Gastroenterol J, 7, pp.496~506 (2019)
42. Kang B, "Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric Crohn’s disease", J Crohns Colitis, 13, pp.189~197 (2019)

관련 논문AI추천